CDK4 and breast cancer: CDKN2A loss, that promotes cell cycle progression by increasing CDK4/6 activity27, has been reported in therapy exposed BC metastases in different studies22,28, suggesting that this genetic event might contribute to endocrine resistance or tumour progression of metastatic BC.